-+ 0.00%
-+ 0.00%
-+ 0.00%

Cannara net income rises 17% to CAD 4.8 million in Q3 FY26; revenue climbs 16% to CAD 31.8 million

PUBT·07/15/2026 12:05:21
Listen to the news
Cannara net income rises 17% to CAD 4.8 million in Q3 FY26; revenue climbs 16% to CAD 31.8 million
  • Cannara Biotech fiscal Q3 ended May 31, 2026 revenue rose 16% to CAD 31.8 million.
  • Net income climbed to CAD 4.8 million; adjusted EBITDA increased 11% to CAD 8.5 million.
  • Gross profit before fair value adjustments grew to CAD 13.4 million; margin narrowed 2 percentage points to 42%.
  • Operating cash flow fell to CAD 5.7 million; free cash flow dropped to CAD 1.3 million on higher Valleyfield capital spending.
  • Distribution exceeded 49,000 points in June 2026; Valleyfield capacity rose above 58,000 kg, targeting about 75,000 kg in fiscal 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannara Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONECNPR____9762548) on July 15, 2026, and is solely responsible for the information contained therein.